ReviewInfection and drug resistance2026
Innovative Antibiotics: The Experience of Cefiderocol in Carbapenem-Resistant Gram-Negative Infections.
Review in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant and multidrug-resistant (MDR) Gram-negative infections are rapidly increasing worldwide and represent one of the greatest current challenges in infectious diseases. The introduction of novel beta-lactam agents, including cefiderocol, a siderophore cephalosporin with a unique mechanism of cell entry, has significantly reshaped the therapeutic approach to these difficult-to-treat infections. Six years after its first FDA approval in November 2019, real-world data have provided valuable insights into the use of cefiderocol across diverse clinical scenarios. Overall, evidence confirms its role as an effective therapeutic option able to overcome multiple resistance mechanisms and improve outcomes in infections caused by resistant Gram-negative bacteria, with, however, notable differences among pathogens. Several unsolved issues remain: the emergence of resistance to cefiderocol is an ongoing phenomenon that warrants continuous surveillance; moreover, the benefit of combination therapy over monotherapy remains uncertain, as current real-life data do not demonstrate clear advantages, and randomized controlled trials are lacking. The aim of this review is to provide an updated overview of real-life evidence on cefiderocol, outlining its role, limitations, and future perspectives in the management of carbapenem-resistant and MDR Gram-negative infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.